Merck & Co., Inc. (NYSE:MRK) This autumn 2024 Outcomes Conference Title February 4, 2025 9:00 AM ET
Agency People
Peter Dannenbaum – Senior Vice President, Investor Relations
Rob Davis – Chairman and Chief Authorities Officer
Caroline Litchfield – Chief Financial Officer
Dr. Dean Li – President of Merck Evaluation Labs
Conference Title People
Umer Raffat – Evercore ISI
Terence Flynn – Morgan Stanley
Luisa Hector – Berenberg
Mohit Bansal – Wells Fargo
Daina Graybosch – Leerink Companions
Geoff Meacham – Citi
Chris Schott – JPMorgan
Tim Anderson – Monetary establishment of America
Akash Tewari – Jefferies
Trung Huynh – UBS
Vamil Divan – Guggenheim
Courtney Breen – Bernstein
James Shin – Deutsche Monetary establishment
Operator
Thanks for standing by. Welcome to the Merck & Agency This autumn Product sales and Earnings Conference Title. Proper now, all people are in a listen-only mode until the question-and-answer session of right now’s conference. [Operator Instructions] This identify is being recorded. You in all probability have any objections, you can disconnect for the time being.
I’d now like to indicate the choice over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you can begin.
Peter Dannenbaum
Thanks, Shirley, and good morning, everyone. Welcome to Merck’s fourth quarter 2024 conference identify. Speaking on right now’s identify is perhaps Rob Davis, Chairman and Chief Authorities Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Evaluation Labs.
Sooner than we get started, I might want to degree out that now now we have devices in our GAAP outcomes akin to acquisition related charges, restructuring costs and positive completely different devices that now now we have excluded from our non-GAAP outcomes. There’s a reconciliation in our press launch.
I could even remind you that a number of of the statements that we make right now is also thought-about forward wanting statements contained in the meaning of the Protected
